Coronavirus vaccine update: The ministry also said that India has eight coronavirus vaccine candidates in the making. Out of the eight, two have applied for emergency use authorisation

The cause of this disease is probed to be the existence of organochlorine substances by medical experts.

As promised, SII has applied for emergency use nod before 2020: Adar Poonawalla Adar Poonawalla, the head of vaccine-making company Serum Institute of India (SII), on Monday informed the company has applied for an emergency use authorisation for Covishield coronavirus vaccine to the Drugs Controller General of India (DCGI). Serum Institute, which is the world's largest vaccine producer by volume, has become the second company to apply for the emergency authorisation after Pfizer India. CO...

After American drug maker Pfizer and Pune-based Serum Institute, Bharat Biotech is the third company to apply for emergency use authorisation for its COVID-19 vaccine to the DCGI

Serum Institute, which is the world's largest vaccine producer by volume, has become the second company to apply for the emergency authorisation after Pfizer India

As per the Indian Council of Medical Research (ICMR), Serum Institute has manufactured four crore doses of the vaccine under the at-risk manufacturing and stockpiling licence obtained from the DCGI

The National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) was constituted under the chairmanship of Member (Health) of Niti Aayog V K Paul on August 7 to prepare a strategy for the roll-out of COVID-19 vaccine

Total number of people who have recuperated from disease has crossed 91 lakh, pushing national recovery rate to 94.37 per cent, according to Union Health Ministry data

 Bharat Biotech said its vaccine is safe and efficacious  after Haryana Home Minister Anil Vij tested positive for the viral disease despite taking the first shot of the medication

The vaccine developer said on Saturday that the Covaxin clinical trials are based on a 2-dose routine, the two doses are administered 28 days apart and vaccine efficacy will be determined 14 days post the second dose

The 67-year-old BJP leader, who's also the home minister in the Khattar Cabinet, has requested everyone who might have come in his contact to get tested. He was the first volunteer in the phase three trials for Covaxin to get the vaccine shot

COVID-19 vaccine trial updates: AIIMS director Dr Randeep Guleria has pinned his hopes on the five coronavirus vaccine candidates which are in varying stages of trials across India

However, VK Paul, who heads the National Task Force on COVID-19, had said in November that the arrival of the Pfizer vaccine in India might take months.

The total coronavirus cases mounted to 95,34,964 with 35,551 new infections being reported in a day, while the death toll climbed to 1,38,648 with 526 new fatalities

Policybazaar announces insurance products that cover job losses; SEBI relaxes compliance requirements for depository  participants, trading members, clearing corporations and KYC registration agencies regarding submission of reports; auto sector revival hits a speed breaker in November. Watch this and more on News Blast.

It is the second time that Novavax, which already has a late-stage UK trial underway, has rescheduled the Phase 3 trial after first flagging an October start, hampered by issues in scaling up its manufacturing

The total coronavirus cases mounted to 94,99,413, with 36,604 new infections being reported in a day, while the death toll climbed to 1,38,122 with 501 new fatalities

Auto sector revival hits a speed breaker in November With the end of the festive season in the middle of November, revival in demand for automobiles in India has started to wane. Three continual months of growth led many to believe a strong revival was well and truly on. Instead, it slowed down 8.92 per cent on annual basis. This confirms auto sector's worst fear that the revival was merely on the back of pent up demand which would be unsustainable beyond festive season.OYO has $1 billion ...

Union health secretary Rajesh Bhushan says the adverse event during recent clinical trials will not affect the timelines in any manner whatsoever

A 40-year-old man who was a volunteer in the third phase of the ''Covidshield'' vaccine trial in Chennai has alleged serious side effects, including a virtual neurological breakdown and impairment of cognitive functions